News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Gustavo Viani: A New Era for Biliary Tract Cancers
Gustavo Viani/sbradioterapia.com.br
Aug 17, 2025, 10:05

Gustavo Viani: A New Era for Biliary Tract Cancers

Gustavo Viani, Associate Professor at Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared on LinkedIn: about a recent paper by Han Xiao et al. published on JAMA Network:

“A New Era for Biliary Tract Cancers: ACCORD Trial Proves the Power of RT + Immunotherapy

Objective

  • To assess whether camrelizumab + capecitabine + radiotherapy improves survival compared with observation after curative surgery for EHC and GBC.

Methods

  • Design: Randomized clinical trial (ACCORD, 2020–2022)
  • Population: 93 patients with resected EHC/GBC
  • Intervention: Camrelizumab every 3 weeks → capecitabine with concurrent RT
  •  Control: Observation only
  • Endpoints: Overall survival (OS, primary), recurrence-free survival (RFS), safety

Results

  • OS at 3 years: 58% vs. 31% (HR 0.43; p=0.004)
  • RFS at 3 years: 40% vs. 17% (HR 0.46; p<0.001)
  •  Well tolerated: no treatment-related deaths, only 13% with delay in immunotherapy

Clinical Impact

  • This trial provides robust evidence that combining immunotherapy with adjuvant chemoradiation significantly increases survival in this challenging setting. It opens a new path for standardizing adjuvant therapy in resectable biliary tract cancers (EHC/GBC), historically lacking effective strategies.”

Gustavo Viani

Title: Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer

Authors: Han Xiao, Jiansong Ji, Shaoqiang Li, Jiaming Lai, Guangyan Wei, Jian Wu, Wei Chen, Wenxuan Xie, Shutong Wang, Liangliang Qiao, Jianfei Tu, Shunli Shen, Zhenwei Peng

Read the full article.

Gustavo Viani

More posts featuring Gustavo Viani.

Biliary tract cancers cancer Guangyan Wei Gustavo Viani Han Xiao Jiaming Lai Jian Wu Jianfei Tu Jiansong Ji Liangliang Qiao OncoDaily Oncology Shaoqiang Li Shunli Shen Shutong Wang UNESP Wei Chen Wenxuan Xie Zhenwei Peng
Special Coverage
Insight
Aug 17, 2025, 10:05
Gustavo Viani: A New Era for Biliary Tract Cancers
Positive
Aug 17, 2025, 10:02
Creighton University Launched its First General Surgery Residency Journal
Voices
Aug 17, 2025, 09:49
Bruno Christian Köhler: Shaping Clinical Trials and Precision Oncology in Northern Germany
Voices
Aug 17, 2025, 09:33
Drew Moghanaki Highlights Cedars Sinai Report on SABR and Thoracic Surgery
Voices
Aug 17, 2025, 09:14
Binaytara Foundation Shared Highlights from Day 1 of Seattle Cellular Therapy Summit 2025
Career Updates
Aug 17, 2025, 09:14
Mark Exley: Appointment as Visiting Professor at Imperial College London
Opinion
Aug 17, 2025, 09:08
Olubukola Ayodele: Charity Shouldn’t Be a Substitute for Women’s Health Equity
Positive
Aug 17, 2025, 08:52
Celebrating NCODA’s Oncology Institute Chairs and Partner Chairs
Voices
Aug 17, 2025, 08:41
Catherine Mwaba: Championing Equity in Cancer Care Through Radiotherapy
Insight
Aug 17, 2025, 08:37
Himanshu Mishra: High-Dose Ascorbic Acid Reverses Immunotherapy Resistance in NSCLC
Voices
Aug 17, 2025, 08:01
Niranjala Siriwardena: The Hidden Work of Advocating for Your Rights After Cancer
Science
Aug 17, 2025, 07:56
Doan Ngo: A Big Year for Newcastle Centre of Excellence in Cardio-Oncology!